Difference between revisions of "Coagulation Tests"

From WikiVet English
Jump to navigation Jump to search
(109 intermediate revisions by 7 users not shown)
Line 1: Line 1:
{{OpenPagesTop}}Also known as: '''''coagulation profile — clotting profile — clotting tests — tests of haemostasis
+
{{unfinished}}
[[Image:Coagulation Cascade.jpg|thumb|right|350px|Coagulation cascade. Source: Wikimedia Commons; Author: Joe D (2007)]]
 
[[Image:LH_Platelet_Histology.jpg|thumb|right|<center><p>'''Platelets'''</p><sup>©RVC 2008</sup></center>]]
 
Normally, [[Normal Mechanisms of Haemostatic Control|haemostastis]] is maintained by three key events: 
 
*'''Primary haemostasis''' involves platelets and the blood vessels themselves and is triggered by injury to a vessel - platelets become activated, adhere to endothelial connective tissue and aggregate with other platelets. A fragile plug is formed which helps to stem haemorrhage from the vessel. Substances released from platelets during primary haemostasis include vasoactive compounds to induce vasoconstriction and other mediators that cause continued platelet activation and aggregation, as well as contraction of the platelet plug. Primary haemostasis ceases once defects in the vessels are sealed and bleeding stops.
 
*'''Secondary haemostasis''' occurs when proteinaceous clotting factors interact in a cascade to produce fibrin to reinforce the clot. Two arms of the cascade are activated simultaneously to achieve coagulation: the intrinsic and extrinsic pathways. The intrinsic pathway is activated by contact with collagen due to vessel injury and involves the clotting factors XII, XI, IX and VIII. The extrinsic pathway is triggered by tissue injury and is effected via factor VII. These pathways progress independently before converging at the common pathway, which involves the factors X, V, II and I and ultimately results in the formation of fibrin from fibrinogen. Factors II, VII, IX and X are dependent upon vitamin K to become active.
 
*'''Fibrinolysis''' is the final stage of restoring haemostasis - it prevents uncontrolled, widespread clot formation and breaks down the fibrin within blood clots.  The two most important anticoagulants involved in fibrinolysis are antithrombin III (ATIII) and Protein C. The end products of fibinolysis are fibrin degratation products (FDPs).
 
 
 
  
 +
Also known as: coagulation profile, clotting profile, clotting tests.
  
Abnormalities can develop in any of the components of haemostasis. Disorders of primary haemostasis include [[Haemorrhagic_Disease_Pathophysiology#Vascular_Fragility|vessel defects]] (i.e. vasculitis), [[Platelet_Abnormalities#Thrombocytopaenia|thrombocytopenia]] (due to decreased production or increased destruction) and [[Platelet Abnormalities|abnormalities in platelet function]] (e.g. congenital defects). These lead to the occurence of multiple minor bleeds and prolonged bleeding times; petechial or ecchymotic [[Haemorrhage|haemorrhages]] may be seen for example, on the skin and mucous membranes, or ocular bleeds may arise. Generally, intact secondary haemostasis prevents major haemorrhage in disorders of primary haemostasis. When secondary haemostasis is abnormal, [[Haemorrhage|larger bleeds]] are frequently seen. Haemothorax, haemoperitoneum, or haemoarthrosis may occur, in addition to subcutaneous and intramuscular haemorrhages. Petechiae and ecchymoses are not usually apparent, as intact primary haemostasis prevents minor capillary bleeding. Examples of secondary haemostatic disorders include [[:Category:Coagulation Defects|clotting factor deficiencies]] (e.g. hepatic failure, vitamin K deficiency, hereditary disorders) and circulation of substances inhibitory to coagulation (FDPs in [[Disseminated Intravascular Coagulation|disseminated intravascular coagulation]], [[Systemic Lupus Erythematosus|lupus]] anticoagulant). If fibrinolysis is defective, thrombus formation and infarctions may result. Thrombus formation may be promoted by vascular damage, circulatory stasis or changes in anticoagulants or procoagulants. For example, ATIII may be decreased. This can occur by loss due to glomerular disease or accelerated consumption in disseminated intravascular coagulation or sepsis.
+
==Introduction==
  
It is therefore important that all aspects of haemostasis can be independently evaluated. This will help to identify the phase affected and to pinpoint what the abnormality is. There are tests available to assess primary haemostasis, secondary haemostasis and fibrinolysis.
+
===Haemostasis===
 +
[[Image:Coagulation Cascade.jpg|thumb|right|350px|oagulation cascade. Source: Wikimedia Commons; Author: Joe D (2007)]]
 +
Normally, haemostastis is maintained by three key events. The first stage, primary haemostasis, involves platelets and the blood vessels themselves. It is triggered by injury to a vessel, and platelets become activated, adhere to endothelial connective tissue and aggregate with other platelets. A fragile plug is thus formed which helps to stem haemorrhage from the vessel. Substances are released from platelets during primary haemostasis. Vasoactive compounds give vasoconstriction, and other mediators cause continued platelet activation and aggregation, as well as contraction of the platelet plug. Primary haemostasis ceases once defects in the vessels are sealed and bleeding stops.
 +
 
 +
The platelet plug formed by primary haemostasis is fragile and must be reinforced in order to provide longer-term benefit. In secondary haemostasis, proteinaceous clotting factors interact in a cascade to produce fibrin to reinforce the clot. Two arms of the cascade are activated simultaneously to achieve coagulation: the intrinsic and extrinsic pathways. The intrinsic pathway is activated by contact with collagen due to vessel injury and involves the clotting factors XII, XI, IX and VIII. The extrinsic pathway is triggered by tissue injury and is effected via factor VII. These pathways progress independently before converging at the common pathway, which involves the factors X, V, II and I and ultimately results in the formation of fibrin from fibrinogen. Factors I, VII, IX and X are dependent upon vitamin K to become active.
 +
 
 +
The end product of haemostasis is a solid clot of fused platelets enclosed in a mesh of fibrin strands. It is important that uncontrolled, widespread clot formation is prevented, and so a fibrinolytic system exists to breakdown fibrin within blood clots.  The two most important anticoagulants involved in fibrinolysis are antithrombin III (ATIII) and Protein C. The end products of fibinolysis are fibrin degratation products (FDPs).
 +
 
 +
===Disorders of Haemostasis===
 +
 
 +
Abnormalities can develop in any of the components of haemostasis. Disorders of primary haemostasis include vessel defects (i.e. vasculitis), thrombocytopenia (due to decreased production or increased destruction) and abnormalities in platelet function (e.g. congenital defects, disseminated intravascular coagulation). These lead to the occurence of multiple minor bleeds and prolonged bleeding. For example, petechial or ecchymotic haemorrhages may be seen on the skin and mucous membranes, or ocular bleeds may arise. Generally, intact secondary haemostasis prevents major haemorrhage in disorders of primary haemostasis. When secondary haemostasis is abnormal, larger bleeds are frequently seen. Haemothroax, haemoperitoneum, or haemoarthrosis may occur, in addition to subcutaneous and intramuscular haemorrhages. Petechiae and ecchymoses are not usually apparent, as intact primary haemostasis prevents minor capillary bleeding. Examples of secondary haemostatic disorders include clotting factor deficiencies (e.g. hepatic failure, vitamin K deficiency, hereditary disorders) and circulation of substances inhibitory to coagulation (FDPs in disseminated intravascular coagulation, lupus anticoagulant). If fibrinolysis is defective, thrombus formation and infarctions may result. Thrombus formation may be promoted by vascular damage,  circulatory stasis or changes in anticoagulants or procoagulants. For example, ATIII may be decreased. This can occur by loss due to glomerular disease or accelarated consumption in disseminated intravascular coagulation or sepsis.
 +
 
 +
It is therefore important that all aspects of haemostasis can be evaluated. This will help to identify the phase affected and to pinpoint what the abnormality is. There are tests available to assess primary haemostasis, secondary haemostasis and fibrinolysis.
  
 
==Tests Evaluating Primary Haemostasis==
 
==Tests Evaluating Primary Haemostasis==
  
Primary haemostasis is dependent on the activity of platelets and, to a lesser extent, the blood vessels themselves. [[Thrombocytes|Platelets]] are the smallest solid formed component of blood, and are non-nucleated, flattened disc-shaped structures<sup>1</sup>. Their activity leads to vascoconstriction and the formation of platelet plugs to occlude vessel defects. Platelets develop in the bone marrow, and have a life span of around 7.5 days. Around two thirds of platelets are found in the circulation at any one time, with the remainder residing in the spleen<sup>1</sup>.
+
Primary haemostasis is dependent on the activity of platelets and, to a lesser extent, the blood vessels themselves. Platelets are the smallest solid formed component of blood, and are non-nucleated, flattened disc-shaped structures<sup>1</sup>. Their activity leads to vascoconstriction and the formation of platelet plugs to occlude vessel defects. Platelets develop in the bone marrow, and have a life span of around 7.5 days. Around two thirds of platelets are found in the circulation at any one time, with the remainder residing in the spleen<sup>1</sup>.
  
Apart from unusual cases involving vasculitis, there are two causes of defects in primary haemostasis: [[Platelet_Abnormalities#Thrombocytopaenia|thrombocytopenia]] (reduced platelet number), or [[Platelet_Abnormalities#Thrombocytopathia|thrombocytopathia]] (defective platelet function)<sup>2</sup>.
+
Apart from unusual cases involving vasculitis, there are two causes of defects in primary haemostasis: thrombocytopenia (reduced platelet number), or thrombocytopathia (defective platelet function)<sup>2</sup>.
  
 
===Platelet Number===
 
===Platelet Number===
A platelet count can give valuable information in all critically ill animals and is an essential laboratory test for patients where there are concerns about abnormal bleeding. Platelet numbers may be rapidly estimated by examination of a stained blood smear, or quantified by manual or automated counting techniques. [[Platelet_Abnormalities#Artefactual_or_spurious_thrombocytopaenia|Platelet clumping]] can give an artificially low platelet count when using manual or automated counting methods. To estimate the platelet number using a blood smear, the slide should first be scanned for evidence of clumping that would artificially reduce the count. The average number of platelets in ten oil-immersion fields should be counted, and a mean calculated. Each platelet in a high-power field represents 15,000 platelets per microlitre<sup>2</sup>. A "normal" platelet count therefore gives around 10-15 platelets per oil-immersion field.
 
  
The reference range given for platelet number is usually around 200-500x10<sup>9</sup> per litre, although this varies depending on the laboratory equipment used. Clinical signs due to thrombocytopenia are not commonly encountered until the platelet count drops below 50x10<sup>9</sup>/l, when increased bleeding times may be seen. Haemorrhage during surgery becomes a concern with counts lower than 20x10<sup>9</sup>/l, and spontaneous bleeding arises when platelets are fewer than 5x10<sup>9</sup>/l<sup>2</sup>. These cut-offs are lowered if platelet function is concurrently affected by other factors such as the use of non-steroidal anti-inflammatory drugs<sup>1</sup>.
+
A platelet count can give valuable information in all critically ill animals and is an essential laboratory tests for patients with bleeding concerns. Platelet numbers may be rapidly estimated by examination of a stained blood smear, of quantified by manual or automated counting techniques. To estimate the platlet number using a blood smear, the slide should first be scanned for evidence of clumping that would artificially reduce the count. The average number of platelets in ten oil-immersion fields should be counted, and a mean calculated. Each platelet in a high-power field represents 15,000 platelets per microlitre<sup>2</sup>. A "normal" platelet count therefore gives aroung 10-15 platelets per oil-immersion field.
 +
 
 +
The reference range given for platelet number is usually around 200-500x10<sup>9</sup> per litre, although this varies depending on the laboratory used. Clinical signs due to thrombocytopenia are not commonly encountered until the platelet count drops below 50X10<sup>9</sup>/l, when increased bleeding times may be seen. Haemorrhage during surgery becomes a concern with counts lower than 20X10<sup>9</sup>/l, and spotaneous bleeding arises when platelets are fewer than 5X10<sup>9</sup>/l<sup>2</sup>. These cut-offs are lowered if platelet function is concurrently affected, for example by the use of non-steroidal anti-inflammatory drugs.
 +
 
 +
===Buccal Mucosal Bleeding Time===
  
 +
The buccal mucosal bleeding time is a simple test that gives a rapid assessment of platelet function, providing platelet numbers are normal. If platelet numbers are below 50x10<sup>9</sup>l, this test should not be performed since bleeding may not be easily stopped.
  
The buccal mucosal bleeding time is a simple test that gives a rapid assessment of platelet function, providing platelet numbers are normal. If platelet numbers are below 50x10<sup>9</sup>/l, this test should not be performed since the results will be affected by thrombocytopenia, making them unreliable. The small wound inflicted may also not stop bleeding easily.
+
When a small slit is made in the skin, the hemostatic mechanisms necessary for coagulation are activated. Without the aid of external pressure, bleeding usually stops within 7 to 9 minutes.
 +
Technique
  
To perform the BMBT test, a standardised tool producing a uniform incision is used to incise the buccal mucosa of the upper lip<sup>2,3</sup>, and the time between making the incision and the cessation of bleeding is measured<sup>2</sup>. During the procedure the lip should be kept turned outwards, with excess blood being gently absorbed at a site away from the incision, without disturbing clot formation or applying pressure. Normally, bleeding should stop within 3 minutes, and a BMBT of greater than 5 minutes is considered prolonged<sup>2</sup>.
+
The test is performed using a disposable template that produces a uniform incision. The incision, either horizontal or vertical, is placed on the lateral aspect of the forearm, about 5 cm below the antecubital fossa, after a blood pressure cuff has been inflated to approximately 40 mm Hg. Blood may be absorbed off the skin, but care must be taken to avoid pressure. The time is measured from the moment of incision to the moment bleeding stops. The time may vary based on the commercial template used, the direction of the incision, and the location on the arm. Each institution must establish its own upper limits of normal.
 +
Basic Science
  
Acquired platelet function abnormalities can be drug induced, for example by [[NSAIDs|non-steroidal anti-inflammatory drugs]]<sup>2,3</sup>, or can be secondary to [[Uraemia|uraemia]]. Hereditary defects in platelet function also exist, and [[Coagulation_Factor_Deficiency#Von_Willebrand.27s_Disease|von Willebrand's disease]] is the most common of these.
+
The vascular platelet phase of hemostasis consists of a primary vasoconstriction that serves to decrease blood flow, followed by adherence of platelets to the ruptured endothelium (adhesion) and each other (aggregation). This platelet aggregate, called the platelet plug, stops the bleeding and forms a matrix for the clot. The bleeding time is an excellent screening test for the vascular platelet phase of hemostasis. It depends on an intact vasospastic response in a small vessel and an adequate number of functionally active platelets.
 +
Clinical Significance
  
The BMBT is influenced by all the aspects of this phase, including vasoconstriction, platelet adherence and plately aggregation. Although this makes BMBT an effective screening test for the vascular/platelet (primary) phase of haemostasis, it also means it is not purely a test for thrombocytopathia, as it is often considered: BMBT depends on an intact vasospastic response and adequate platelet numbers as well as platelet function<sup>3</sup>. BMBT is a fairly crude test, and has been found to be normal in some patients with a known platelet function disorder and vice versa<sup>3</sup>. The results of this test therefore should be interpreted with some caution.
+
Patients with abnormalities of the vascular platelet phase of hemostasis present with purpura (petechiae and ecchymoses) and spontaneous bruising. They may have mucosal bleeding and fundus hemorrhages. Commonly, the problem is either thrombocytopenia, easily evaluated by a platelet count, or abnormal platelet function, which can be diagnosed with platelet function studies. The most common acquired platelet function abnormalities are drug induced (aspirin and the nonsteroidal anti-inflammatory agents) and uremia. The most common hereditary abnormality is von Willebrand's disease.
  
 
==Tests Evaluating Secondary Haemostasis==
 
==Tests Evaluating Secondary Haemostasis==
  
Secondary haemostasis describes the formation of a cross linked fibrin meshwork in the blood clot and is dependent on soluble coagulation factors. Abnormalities in secondary coagulation can occur if there are insufficient coagulation factors, inactive coagulation factors or inhibition of factors. To recap, the soluble coagulation factors are traditionally divided into the intrinsic, extrinsic and common pathways.
+
===ACT===
 +
 
 +
===PT===
 +
 
 +
===(A)PTT===
 +
Definition
 +
 
 +
The aPTT measures the time necessary to generate fibrin from initiation of the intrinsic pathway (Figure 157.1). Activation of factor XII is accomplished with an external agent (e.g., kaolin) capable of activating factor XII without activating factor VII. Since platelet factors are necessary for the cascade to function normally, the test is performed in the presence of a phospholipid emulsion that takes the place of these factors. The classic partial thromboplastin time depends on contact with a glass tube for activation. Since this is considered a difficult variable to control, the "activated" test uses an external source of activation.
 +
Technique
 +
 
 +
Citrated plasma, an activating agent, and phospholipid are added together and incubated at 37°C. Calcium is added, and the time necessary for the clumping of kaolin is measured. The normal time is usually reported as less than 30 to 35 seconds depending on the technique used. In fact, there is a normal range of about 10 seconds (e.g., 25 to 35), and decreased values ("short") may also be abnormal.
 +
Basic Science
 +
 
 +
This test is abnormal in the presence of reduced quantities of factors XII, IX, XI, VIII, X, V, prothrombin, and fibrinogen (all integral parts of the "intrinsic" and "common" pathway. It is usually prolonged if a patient has less than approximately 30% normal activity. It can also be abnormal in the presence of a circulating inhibitor to any of the intrinsic pathway factors. The differentiation of inhibitors from factor depletion is important and can best be accomplished by a mixing study in which patient and normal plasma are combined in a 1:1 ratio and the test is repeated on the mixed sample. If the abnormal value is corrected completely, the problem is factor deficiency. If the result does not change or the abnormality is corrected only partially, an inhibitor is present. This difference stems from the above mentioned fact that the aPTT will be normal in the presence of 50% normal activity.
 +
Clinical Significance
 +
 
 +
The aPTT is a good screening test for inherited or acquired factor deficiencies. Inherited disorders including classic hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency, or Christmas disease) are well-known diseases in which the aPTT is prolonged. Other intrinsic and common pathway factors may also be congenitally absent. These conditions are rare but have been described for all factors. A number of kindreds with abnormalities of factor XII activation have been described. They are usually associated with a prolonged aPTT without clinical signs of bleeding. Acquired factor deficiency is common. Vitamin K deficiency, liver dysfunction, and iatrogenic anticoagulation with warfarin are most common. Factor depletion may also occur in the setting of disseminated intravascular coagulation (DIC), prolonged bleeding, and massive transfusion.
  
===Activated Clotting Time===
+
A prolonged aPTT that cannot be completely normalized with the addition of normal plasma can be explained only by the presence of a circulating inhibitor of coagulation. The presence of these inhibitors is almost always acquired, and their exact nature is not always apparent. From a clinical point of view, the most common inhibitors should be considered antithrombins. These compounds inhibit the activity of thrombin on the conversion of fibrinogen to fibrin (Figure 157.1). The two most common inhibitors are heparin, which acts through the naturally occurring protein antithrombin III (AT III), and fibrin degradation products (FDP), formed by the action of plasmin on the fibrin clot and usually present in elevated concentrations in DIC and primary fibrinolysis.
The activated clotting time (ACT) allows rapid evaluation of secondary haemostasis. The ACT is the time taken for 2ml of fresh whole blood to clot in a tube with a contact activator (diatomaceous earth<sup>2</sup>), but an automated analyser can perform a test with a similar principle. The reaction must occur at body temperature to give a reliable indication of haemostatic ability: this can be achieved by the use of a warm water bath, or in an emergency by holding the tubes under an arm.  
 
  
The contact activator used in the ACT test triggers the intrinsic pathway, and so ACT allows assessment of the intrinsic and common pathways. ACT will therefore be prolonged when factors I, II, V, VIII, IX, X, XI or XII are deficient or abnormal, such as in DIC, liver disease, vitamin K antagonist toxicosis or haemophilia A or B<sup>2</sup>. Thrombocytopenia may also increase ACT.
+
Other inhibitors appear to be antibodies. The easiest to understand is the antibody against factor VIII in patients with hemophilia A treated with factor VIII concentrate. Inhibitors against other factors have been described with a variety of diseases that follow a variable course. When characterized, they have been immunoglobulins.
  
===Activated Partial Thromboplastin Time===
+
A particular problem may be seen in patients suffering from systemic lupus erythematosus. These patients may present with a prolonged aPTT without evidence of bleeding. Some present with thrombosis. The abnormality cannot be corrected with normal plasma and has been referred to as the "lupus anticoagulant." This phenomenon does not represent an in vivo problem with the coagulation cascade. Rather, it is a laboratory abnormality caused by the presence of a serum constituent that interferes with the in vitro partial thromboplastin test.
The APTT measures the time necessary to generate fibrin from activation of the intrinsic pathway<sup>3</sup>. It therefore assesses functionality of the components of the intrinsic and common pathways of coagulation. The test is performed on citrated plasma, and so blood should be collected into a sodium citrate tube if the APTT test is to be undertaken. Once a sample is obtained, factor XII is activated by an external agent that will not also activate factor VII, such as kaolin<sup>1, 3</sup>. Since the intrinsic arm of the cascade requires platelet factors to function, the test also provides a phospholipid emuslion in place of these factors. Calcium is added, the preparation is incubated, and the time for clumping of kaolin is measured. Classically, partial thromboplastin time was measured after activation by contact with a glass tube, but use of an external activating agent in the newer, "activated" partial thromboplastin time method makes results more reliable<sup>3</sup>.
 
  
APPT evaluates the same pathways as ACT, and so will be prolonged by abnormalities or deficiencies in factors XII, XI, IX, VIII, X, V, II or I. However, APTT is not affected
+
Occasionally the reported value of the aPTT will be lower than normal. This "shortened" time may reflect the presence of increased levels of activated factors in context of a "hypercoagulable state." It is seen in some patients in the early stages of DIC but should not be considered diagnostic for that entity.
  
{{Learning
+
===PIVKA===
|literature search = [http://www.cabdirect.org/search.html?rowId=1&options1=AND&q1=%22Coagulation%22&occuring1=title&rowId=2&options2=AND&q2=tes*&occuring2=title&rowId=3&options3=AND&q3=&occuring3=freetext&x=65&y=9&publishedstart=yyyy&publishedend=yyyy&calendarInput=yyyy-mm-dd&la=any&it=any&show=all Coagulation Tests publications]
 
|flashcards = [[Equine Internal Medicine Q&A 03]]
 
}}
 
  
==Links==
+
==Tests Evaluating Fibrinolysis==
  
*[http://ahdc.vet.cornell.edu/clinpath/modules/coags/testsf.htm Cornell University Clinical Pathology Modules: Tests of Haemostasis]
+
===Fibrin Degradation Products===
  
 
==References==
 
==References==
Line 60: Line 84:
 
#Fischbach, F T and Dunning, M B (2008) '''A manual of laboratory and diagnostic tests''', ''Lippincott Williams and Wilkins''.  
 
#Fischbach, F T and Dunning, M B (2008) '''A manual of laboratory and diagnostic tests''', ''Lippincott Williams and Wilkins''.  
 
#Hopper, K (2005) Interpreting coagulation tests. ''Proceedings of the 56th conference of La Società culturale italiana veterinari per animali da compagnia''.
 
#Hopper, K (2005) Interpreting coagulation tests. ''Proceedings of the 56th conference of La Società culturale italiana veterinari per animali da compagnia''.
#Walker, K H et al (1990) '''Clinical Methods: The History, Physical and Laboratory Examinations (Third Edition)''', ''Butterworths''.
 
#[http://ahdc.vet.cornell.edu/clinpath/modules/coags/pivka.htm Cornell University Clinical Pathology Modules: Tests of Haemostasis - PIVKA]
 
 
#Howard, M R and (2008) '''Haematology: an illustrated colour text''', ''Elsevier Health Sciences''.
 
#Howard, M R and (2008) '''Haematology: an illustrated colour text''', ''Elsevier Health Sciences''.
#Mair, TS & Divers, TJ (1997) '''Self-Assessment Colour Review Equine Internal Medicine''' ''Manson Publishing Ltd''
+
#Walker, K H et al (1990) '''Clinical Methods: The history, Physical and Laboratory Examinations (Third Edition)''', ''Butterworths''.
 
+
[[Category:To Do - Blood]][[Category:To Do - Lizzie]]
 
 
{{review}}
 
 
 
{{OpenPages}}
 
[[Category:Blood Samples and Coagulation Tests]]
 
[[Category:Clinical Pathology]]
 
[[Category:Expert Review]]
 

Revision as of 12:31, 25 August 2010



Also known as: coagulation profile, clotting profile, clotting tests.

Introduction

Haemostasis

oagulation cascade. Source: Wikimedia Commons; Author: Joe D (2007)

Normally, haemostastis is maintained by three key events. The first stage, primary haemostasis, involves platelets and the blood vessels themselves. It is triggered by injury to a vessel, and platelets become activated, adhere to endothelial connective tissue and aggregate with other platelets. A fragile plug is thus formed which helps to stem haemorrhage from the vessel. Substances are released from platelets during primary haemostasis. Vasoactive compounds give vasoconstriction, and other mediators cause continued platelet activation and aggregation, as well as contraction of the platelet plug. Primary haemostasis ceases once defects in the vessels are sealed and bleeding stops.

The platelet plug formed by primary haemostasis is fragile and must be reinforced in order to provide longer-term benefit. In secondary haemostasis, proteinaceous clotting factors interact in a cascade to produce fibrin to reinforce the clot. Two arms of the cascade are activated simultaneously to achieve coagulation: the intrinsic and extrinsic pathways. The intrinsic pathway is activated by contact with collagen due to vessel injury and involves the clotting factors XII, XI, IX and VIII. The extrinsic pathway is triggered by tissue injury and is effected via factor VII. These pathways progress independently before converging at the common pathway, which involves the factors X, V, II and I and ultimately results in the formation of fibrin from fibrinogen. Factors I, VII, IX and X are dependent upon vitamin K to become active.

The end product of haemostasis is a solid clot of fused platelets enclosed in a mesh of fibrin strands. It is important that uncontrolled, widespread clot formation is prevented, and so a fibrinolytic system exists to breakdown fibrin within blood clots. The two most important anticoagulants involved in fibrinolysis are antithrombin III (ATIII) and Protein C. The end products of fibinolysis are fibrin degratation products (FDPs).

Disorders of Haemostasis

Abnormalities can develop in any of the components of haemostasis. Disorders of primary haemostasis include vessel defects (i.e. vasculitis), thrombocytopenia (due to decreased production or increased destruction) and abnormalities in platelet function (e.g. congenital defects, disseminated intravascular coagulation). These lead to the occurence of multiple minor bleeds and prolonged bleeding. For example, petechial or ecchymotic haemorrhages may be seen on the skin and mucous membranes, or ocular bleeds may arise. Generally, intact secondary haemostasis prevents major haemorrhage in disorders of primary haemostasis. When secondary haemostasis is abnormal, larger bleeds are frequently seen. Haemothroax, haemoperitoneum, or haemoarthrosis may occur, in addition to subcutaneous and intramuscular haemorrhages. Petechiae and ecchymoses are not usually apparent, as intact primary haemostasis prevents minor capillary bleeding. Examples of secondary haemostatic disorders include clotting factor deficiencies (e.g. hepatic failure, vitamin K deficiency, hereditary disorders) and circulation of substances inhibitory to coagulation (FDPs in disseminated intravascular coagulation, lupus anticoagulant). If fibrinolysis is defective, thrombus formation and infarctions may result. Thrombus formation may be promoted by vascular damage, circulatory stasis or changes in anticoagulants or procoagulants. For example, ATIII may be decreased. This can occur by loss due to glomerular disease or accelarated consumption in disseminated intravascular coagulation or sepsis.

It is therefore important that all aspects of haemostasis can be evaluated. This will help to identify the phase affected and to pinpoint what the abnormality is. There are tests available to assess primary haemostasis, secondary haemostasis and fibrinolysis.

Tests Evaluating Primary Haemostasis

Primary haemostasis is dependent on the activity of platelets and, to a lesser extent, the blood vessels themselves. Platelets are the smallest solid formed component of blood, and are non-nucleated, flattened disc-shaped structures1. Their activity leads to vascoconstriction and the formation of platelet plugs to occlude vessel defects. Platelets develop in the bone marrow, and have a life span of around 7.5 days. Around two thirds of platelets are found in the circulation at any one time, with the remainder residing in the spleen1.

Apart from unusual cases involving vasculitis, there are two causes of defects in primary haemostasis: thrombocytopenia (reduced platelet number), or thrombocytopathia (defective platelet function)2.

Platelet Number

A platelet count can give valuable information in all critically ill animals and is an essential laboratory tests for patients with bleeding concerns. Platelet numbers may be rapidly estimated by examination of a stained blood smear, of quantified by manual or automated counting techniques. To estimate the platlet number using a blood smear, the slide should first be scanned for evidence of clumping that would artificially reduce the count. The average number of platelets in ten oil-immersion fields should be counted, and a mean calculated. Each platelet in a high-power field represents 15,000 platelets per microlitre2. A "normal" platelet count therefore gives aroung 10-15 platelets per oil-immersion field.

The reference range given for platelet number is usually around 200-500x109 per litre, although this varies depending on the laboratory used. Clinical signs due to thrombocytopenia are not commonly encountered until the platelet count drops below 50X109/l, when increased bleeding times may be seen. Haemorrhage during surgery becomes a concern with counts lower than 20X109/l, and spotaneous bleeding arises when platelets are fewer than 5X109/l2. These cut-offs are lowered if platelet function is concurrently affected, for example by the use of non-steroidal anti-inflammatory drugs.

Buccal Mucosal Bleeding Time

The buccal mucosal bleeding time is a simple test that gives a rapid assessment of platelet function, providing platelet numbers are normal. If platelet numbers are below 50x109l, this test should not be performed since bleeding may not be easily stopped.

When a small slit is made in the skin, the hemostatic mechanisms necessary for coagulation are activated. Without the aid of external pressure, bleeding usually stops within 7 to 9 minutes. Technique

The test is performed using a disposable template that produces a uniform incision. The incision, either horizontal or vertical, is placed on the lateral aspect of the forearm, about 5 cm below the antecubital fossa, after a blood pressure cuff has been inflated to approximately 40 mm Hg. Blood may be absorbed off the skin, but care must be taken to avoid pressure. The time is measured from the moment of incision to the moment bleeding stops. The time may vary based on the commercial template used, the direction of the incision, and the location on the arm. Each institution must establish its own upper limits of normal. Basic Science

The vascular platelet phase of hemostasis consists of a primary vasoconstriction that serves to decrease blood flow, followed by adherence of platelets to the ruptured endothelium (adhesion) and each other (aggregation). This platelet aggregate, called the platelet plug, stops the bleeding and forms a matrix for the clot. The bleeding time is an excellent screening test for the vascular platelet phase of hemostasis. It depends on an intact vasospastic response in a small vessel and an adequate number of functionally active platelets. Clinical Significance

Patients with abnormalities of the vascular platelet phase of hemostasis present with purpura (petechiae and ecchymoses) and spontaneous bruising. They may have mucosal bleeding and fundus hemorrhages. Commonly, the problem is either thrombocytopenia, easily evaluated by a platelet count, or abnormal platelet function, which can be diagnosed with platelet function studies. The most common acquired platelet function abnormalities are drug induced (aspirin and the nonsteroidal anti-inflammatory agents) and uremia. The most common hereditary abnormality is von Willebrand's disease.

Tests Evaluating Secondary Haemostasis

ACT

PT

(A)PTT

Definition

The aPTT measures the time necessary to generate fibrin from initiation of the intrinsic pathway (Figure 157.1). Activation of factor XII is accomplished with an external agent (e.g., kaolin) capable of activating factor XII without activating factor VII. Since platelet factors are necessary for the cascade to function normally, the test is performed in the presence of a phospholipid emulsion that takes the place of these factors. The classic partial thromboplastin time depends on contact with a glass tube for activation. Since this is considered a difficult variable to control, the "activated" test uses an external source of activation. Technique

Citrated plasma, an activating agent, and phospholipid are added together and incubated at 37°C. Calcium is added, and the time necessary for the clumping of kaolin is measured. The normal time is usually reported as less than 30 to 35 seconds depending on the technique used. In fact, there is a normal range of about 10 seconds (e.g., 25 to 35), and decreased values ("short") may also be abnormal. Basic Science

This test is abnormal in the presence of reduced quantities of factors XII, IX, XI, VIII, X, V, prothrombin, and fibrinogen (all integral parts of the "intrinsic" and "common" pathway. It is usually prolonged if a patient has less than approximately 30% normal activity. It can also be abnormal in the presence of a circulating inhibitor to any of the intrinsic pathway factors. The differentiation of inhibitors from factor depletion is important and can best be accomplished by a mixing study in which patient and normal plasma are combined in a 1:1 ratio and the test is repeated on the mixed sample. If the abnormal value is corrected completely, the problem is factor deficiency. If the result does not change or the abnormality is corrected only partially, an inhibitor is present. This difference stems from the above mentioned fact that the aPTT will be normal in the presence of 50% normal activity. Clinical Significance

The aPTT is a good screening test for inherited or acquired factor deficiencies. Inherited disorders including classic hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency, or Christmas disease) are well-known diseases in which the aPTT is prolonged. Other intrinsic and common pathway factors may also be congenitally absent. These conditions are rare but have been described for all factors. A number of kindreds with abnormalities of factor XII activation have been described. They are usually associated with a prolonged aPTT without clinical signs of bleeding. Acquired factor deficiency is common. Vitamin K deficiency, liver dysfunction, and iatrogenic anticoagulation with warfarin are most common. Factor depletion may also occur in the setting of disseminated intravascular coagulation (DIC), prolonged bleeding, and massive transfusion.

A prolonged aPTT that cannot be completely normalized with the addition of normal plasma can be explained only by the presence of a circulating inhibitor of coagulation. The presence of these inhibitors is almost always acquired, and their exact nature is not always apparent. From a clinical point of view, the most common inhibitors should be considered antithrombins. These compounds inhibit the activity of thrombin on the conversion of fibrinogen to fibrin (Figure 157.1). The two most common inhibitors are heparin, which acts through the naturally occurring protein antithrombin III (AT III), and fibrin degradation products (FDP), formed by the action of plasmin on the fibrin clot and usually present in elevated concentrations in DIC and primary fibrinolysis.

Other inhibitors appear to be antibodies. The easiest to understand is the antibody against factor VIII in patients with hemophilia A treated with factor VIII concentrate. Inhibitors against other factors have been described with a variety of diseases that follow a variable course. When characterized, they have been immunoglobulins.

A particular problem may be seen in patients suffering from systemic lupus erythematosus. These patients may present with a prolonged aPTT without evidence of bleeding. Some present with thrombosis. The abnormality cannot be corrected with normal plasma and has been referred to as the "lupus anticoagulant." This phenomenon does not represent an in vivo problem with the coagulation cascade. Rather, it is a laboratory abnormality caused by the presence of a serum constituent that interferes with the in vitro partial thromboplastin test.

Occasionally the reported value of the aPTT will be lower than normal. This "shortened" time may reflect the presence of increased levels of activated factors in context of a "hypercoagulable state." It is seen in some patients in the early stages of DIC but should not be considered diagnostic for that entity.

PIVKA

Tests Evaluating Fibrinolysis

Fibrin Degradation Products

References

  1. Fischbach, F T and Dunning, M B (2008) A manual of laboratory and diagnostic tests, Lippincott Williams and Wilkins.
  2. Hopper, K (2005) Interpreting coagulation tests. Proceedings of the 56th conference of La Società culturale italiana veterinari per animali da compagnia.
  3. Howard, M R and (2008) Haematology: an illustrated colour text, Elsevier Health Sciences.
  4. Walker, K H et al (1990) Clinical Methods: The history, Physical and Laboratory Examinations (Third Edition), Butterworths.